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Abstract
Background: To explore the relationship between adult Attention Deficit/ Hyperactivity Disorder (ADHD),
antistreptococcal titers, ABGA, and recurrent infections during early childhood.
Method: Childhood history of recurrent infections and a blood sample were collected in a sample of DSM-IV adult
outpatients with ADHD. The anti-streptolysin O (ASO), anti-deoxyribonuclease B (anti-DNase B), and anti-basal
ganglia antibodies (ABGA) titers were determined in patient plasma by enzyme-linked immunosorbent assay (ELIS
A). Titers positivity was evaluated following manufacturer’s specifications. Absolute titers were also collected as
continuous variables.
Results: Fourteen out of 22 (63.6%) have had recurrent infections in childhood (i.e., seven, 31.8%, have had
tonsillitis or adenoiditis and seven, 31.8%, have had any other infections). Eighteen patients (81.9%) were positive
for anti-DNase B, five (22.7%) for ASO, and 4 (18.2%) were positive for both of them. Five participants (22.7%) were
ABGA positive, whereas only two (9.1%) were positive for all three antibodies.
Conclusions: patients with ADHD might be more prone to infections during childhood and subclinical
streptococcal infections during adulthood. Moreover, they seem to have an increased risk for basal ganglia
autoimmunity in adulthood. Both infections and the ensuing acquired autoimmunity could influence the
neurodevelopmental process, by contributing, at least in part, to the ADHD pathogenesis.
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Background
ADHD is one of the most prevalent neurodevelopmental
disorders and it is characterized by a persistent pattern
of inattention and/or hyperactivity and/or impulsivity,
leading to functional impairment [1] and several lifetime
consequences [2]. Despite ADHD arises in childhood, it
can persist in adulthood in about half of patients as a
full-criteria disorder (45–57%) [3, 4], whereas a further
37% can show impairing symptoms or a subthreshold
disorder at the 10 years after follow-up [3]. Neuroimag-
ing and neurophysiological studies have consistently
documented that improvement with age in core symp-
toms are accompanied by functional changes in cortical
(right inferior frontal and inferior parietal/precuneus)
and cerebellar regions [5, 6], whereas basal ganglia
anomalies (i.e., right caudate) seem to be a peculiar life-
time feature of ADHD, regardless of adult remission [6,
7]. Studies on structural anomalies and age-by-diagnosis
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interaction in the caudate and putamen have also sup-
ported the pivotal role of subcortical basal ganglia anom-
alies in the pathophysiology of ADHD [8, 9].
Although the etiopathogenesis of ADHD is still un-
clear, a gene by environment model has been proposed
to explain the high family history of the disorder [2, 10,
11]. Probably, a variable and complex interaction be-
tween predisposing genetic and environmental factors
during the early months or years of life could affect the
normal path of neurodevelopment. Considering the
above-mentioned structural and functional evidences,
environmental factors influencing basal ganglia develop-
ment should be worthy of investigation. For instance, a
specific vascular vulnerability of the striatum due to its
positioning in a border zone of arterial supply has
already been suggested by a case-control study reporting
on hypoxic and other perinatal complications [12] and
by a review of some in vivo studies [13]. A more recent
study has documented the negative impact of exposure
to polycyclic aromatic hydrocarbons on the caudate nu-
cleus, even below the legislated annual target levels
established in the European Union [14].
Over the last 20 years, the recognition of the role of
some infections (e.g., group A streptococcus - GAS) in de-
termining acute, somewhat mixed, movement (i.e., Syden-
ham’s chorea) and psychiatric disorders (i.e., obsessive-
compulsive disorders, tic disorder, ADHD), have increased
the attention to infective agents as possible causes of
childhood neurodevelopmental disorders, involving basal
ganglia [15–18]. A molecular mimicry mechanism has also
been proposed to explain the enduring symptoms subse-
quent to GAS infection remission [19, 20]. Moreover, high
titers of GAS infection markers, i.e., anti-streptolysin O
(ASO) and anti-deoxyribonuclease B (anti-DNase B), and
anti-basal ganglia antibodies (ABGA) were found in this
type of disorders [21–23].
Since Kiessling and colleagues [22] have reported a
higher prevalence of distractibility and hyperactivity
among patients with post-streptococcal movement disor-
ders than in controls, a growing number of subsequent
studies have specifically investigated, in different ways, the
relationship between GAS infections, basal ganglia auto-
immunity and ADHD with conflicting results [24–28].
ADHD appears to play an important role in post-
streptococcal basal ganglia disorder at least as much as
obsessive-compulsive and tic disorders even when con-
sidered alone: higher titers of GAS infection markers
were found in children with ADHD than in those with
obsessive-compulsive or tic disorder; ADHD and even
more hyperactivity symptoms significantly predicted
anti-DNase B titer; and ASO titers were correlated with
basal ganglia volume in children with ADHD [26].
More recently, three case-control studies have focused
on GAS infection and ABGA titers of children with
ADHD and without comorbid obsessive-compulsive/tic
disorders [24, 27, 28]. Only one study found higher
ABGA titers among children with ADHD than controls
(30% vs. 15%, [28]), whereas higher titers of ASO and
anti-DNase B were reported in children with ADHD by
two out of three studies [27, 28]. All those inquiring
about GAS infection collecting pharyngeal swabs re-
ported higher rates of positive culture among children
with ADHD than controls [24, 27]. Regardless of the
specific strengths and limitations, they all were con-
ducted on child populations and, taken together with
above-mentioned studies, they suggest a possible predis-
position of patients with ADHD to be infected by GAS,
involving basal ganglia development.
To the best of our knowledge, no studies have assessed
GAS antibodies and ABGA titers in adult patients with
ADHD in an attempt to confirm the lifespan vulnerabil-
ity of this population to GAS infection, which could also,
in some cases, involve basal ganglia autoimmunity.
The aim of the present preliminary study was to ex-
plore ASO, anti-DNase B, and ABGA titers in a sample
of adult outpatients with ADHD.
Methods
This preliminary study was conducted at the adult
ADHD outpatient center of the San Luigi Gonzaga Uni-
versity Hospital (Orbassano, Turin, Italy), between July
1, 2019 and September 1, 2019, on a consecutive sample
of patients newly diagnosed with adult ADHD according
to DSM-IV-TR criteria (age > 18 years). According to the
outpatient service routine, all patients had been screened
for adult ADHD using the Adult ADHD Self Reporting
Scale (ASRS-1.1) screener, and then the DSM-IV ADHD
diagnosis was confirmed through the Diagnostic Inter-
view for Adult ADHD (DIVA 2.0). The severity of
ADHD symptoms was rated by Adult ADHD Investiga-
tion Rating Scale (AISRS).
All patients were asked to participate in the study
signing a written informed consent and a unique identi-
fication code was assigned to each patient, in order to
maintain data anonymity and patient confidentiality.
The research protocol of the present observational study
was approved by the Research Ethics Committee of the
San Luigi Gonzaga University Hospital (Orbassano,
Turin, Italy), therefore the study was conducted in ac-
cordance with the Helsinki Declaration.
During the assessment process, information about the
history of both infections and psychiatric disorders were
collected and patients were also assessed for other psy-
chiatric disorders through an in-depth psychiatric inter-
view. Recurrent infections in childhood (i.e., under 12)
were defined as at least three symptomatic episodes of
infection with fever (e.g., tonsillitis, adenoiditis, glomer-
ulonephritis, or others) per year for at least 1 year.
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Blood samples from patients were collected in potas-
sium ethylenediaminetetraacetic acid (EDTA) - contain-
ing tubes (BD Vacutainer® spray-coated K2EDTA,
Becton, Dickinson and Company, Franklin Lakes, NJ,
USA) at the end of each recruitment. Plasma was sepa-
rated by centrifugation at 24,104 x g at 4 °C for 10 min
and immediately stored at − 80 °C ready for analyses.
Commercial, ready-to-use, microwell ELISA kits were
used for the quantitative determination of plasma con-
centration of ASO (Cat. No MBS038268, MyBioSource
Inc., San Diego, USA), anti-DNase B (Cat. No
MBS7226468, MyBioSource Inc., San Diego, USA), and
ABGA (Cat. No MBS706650, MyBioSource Inc., San
Diego, USA). Sample absorbance values were detected in
a 96-multiwell plate reader (Model 680 Microplate
Reader, Bio-Rad, Milan, Italy) using dual-wavelength re-
cording modes at 450 nm and 655 nm (the latter used as
reference). ELISA protocols instructions, and threshold
values for adults provided by the manufacturer were
adopted. . Thereby, the following values defined patient
positivity: ASO > 200 U/ml; anti-DNase B > 86 ng/ml;
ABGA > 1.18 (as the ratio referred to the negative con-
trol optical density) but absolute titers values were also
collected as continuous variables.
Clinical assessment tools
The ASRS 1.1 [29] is a six-item self-report screener for
adult ADHD, based on the DSM-IV-TR criteria. It was
developed by the World Health Organization (WHO)
and then validated internationally [30]. The screening is
considered positive when at least four answers are above
cut-off value.
The DIVA 2.0 [31] is a validated [32] semistructured
interview to assess the adult patients, according to the
DSM-IV criteria. It investigates DSM-IV inattentive and
hyperactivity/impulsivity symptoms (criterion A) in both
childhood and adulthood, using several real-life exam-
ples to support each question inquiring about 18 DSM-
IV criteria. It also includes explicit questions for age at
onset (i.e., the presence of symptoms before the age of 7
years, criterion B) and other primary psychiatric and/or
substance use disorders (which could better explain the
reported symptoms, criterion E). The last section con-
sists in an in-depth evaluation of the main areas of func-
tioning impacted by ADHD symptoms (criteria C and
D). Furthermore, the collateral information should be re-
ported in both content and source (i.e., the presence of
parents/third parties; school reports).
The AISRS is a validated [33] 18-item scale matching
the DSM-IV criteria. It is divided into two subscales of
nine items each, investigating inattentive and hyperactiv-
ity/impulsivity, respectively. The items are provided with
examples to minimize interrater variability. The scoring
system ranges from zero (none) to three (severe). The
maximum score for each subscale is 27 points, with a
maximum total score of 54.
Statistical analysis
All analyses and calculations were performed using
RStudio for MAC OS (Version 1.1.383, RStudio Inc.,
Boston, MA).
The positivity rate for every titer was calculated. The
distributions of continuous variables were tested by
Shapiro-Wilk’s test. A p-value of 0.05 was used to desig-
nate statistical significance. Mean and standard deviation
(SD) were used to report normally distributed variables,
whereas median (Mdn) and interquartile range (IQR)
were used for nonnormally distributed ones.
Results
A sample of 22 adult outpatients with ADHD was re-
cruited. The sociodemographic and clinical features of
the sample are summarized in Table 1. Little more than
half of the patients were male. The age was not normally
distributed (Shapiro-Wilk’s test W = 0.868, p < .001).
Most of the patients have reached a middle or high
school diploma, but more than a fifth of them have got a
degree. Although the majority of the sample referred
from GPs, psychiatrists, or child neuropsychiatrists, less
than half accessed the adult ADHD center on their own
(Table 1). .
Little more than half of the sample had a predomin-
antly inattentive subtype ADHD. The rate of psychiatric
comorbidity was high but no patient has ever suffered
from tic disorder, obsessive-compulsive disorder or
Sydenham’s chorea (Table 1).
Little more than a third of the sample has had recur-
rent infections with fever in childhood (Table 1)).
As regards antistreptococcal antibodies, 18 patients
(81.9%) had positive anti-DNase B titer, five (22.7%) had
positive ASO titer, four (18.2%) had them both positive.
Five (22.7%) patients were ABGA positive, whereas only
two (9.1%) resulted positive for all three titers. All titers
were nonnormally distributed in the examined popula-
tion (ASO, Median = 114.5, IQR = 82.2, Shapiro-Wilk’s
test W = .792, p < .001; anti-DNase B, Median = 95,
IQR = 17, Shapiro-Wilk’s test W = .915, p = .049; ASO,
Median = .54, IQR = .17, Shapiro-Wilks W test = .661,
p < .001). Within sample subgroups comparison could
not be performed due to low numerosity.
Discussion
This is the first report on anti-GAS antibodies and
ABGA titers in adult patients with ADHD. Although it
is a preliminary study, the magnitude of GAS infections
and basal ganglia autoimmunity in adult patients with
ADHD cannot be considered negligible as a large pro-
portion of the sample was anti-DNase B positive (index
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of prior GAS infections), more than a quarter of the
sample still showed ASO titer positivity (index of recent
GAS infection) and the same amount presents ABGA
positivity (index of acquired autoimmunity). The com-
parison with previous studies conducted on children
with ADHD is challenging because of methods hetero-
geneity, albeit they all excluded patients with tics,
obsessive-compulsive disorder, and Sydenham’s chorea.
On average, the positivity rate of ASO titers reported by
previous studies (ranging from 50 to 60%, [24, 28]) dou-
bled that detected in the present preliminary investiga-
tion, even considering the well-recognized age-related
decrease of the threshold value [34]. Conversely, the
positivity rate of anti-DNase B in our adult sample was
higher than that reported by a prior study on children
with ADHD (81.3% vs. 60%, [24]). The elevation of both
ASO and anti-DNase B above the threshold was found
in less than half proportion of patients than that re-
ported by two of the prior studies (ranging from 50 to
60%, [24, 27]).
All patients were recruited and tested for titers during
summer, the season having the fewest GAS outbursts
[34]. On the one hand, this can partially explain the
lower proportion of positive ASO titers (index of recent
infection) than that registered in previous studies enrol-
ling child patients during all seasons [24, 27, 28]. On the
other hand, it provides further support to our findings
because they should be considered an underestimation
of the actual scenario. Retrospectively collected data on
childhood history of infection suggest a distinctive im-
mune vulnerability of ADHD as almost two-thirds of the
sample showed a variety of recurrent infections, half of
which were tonsillitis or adenoiditis. To our knowledge,
this is the first report on the history of recurrent infec-
tion in adult ADHD. Only a previous study collected this
data in children with ADHD, finding that 18% (n = 7) of
the sample had a history of GAS infections [24]. All par-
ticipants of the present preliminary study were non-
remitter adult ADHD, thus adults who have had ADHD
in childhood but not having current ADHD were not
enrolled (i.e., remitters and subthreshold ADHD pa-
tients). Bearing in mind the ADHD remission rate from
childhood to adulthood (45–57%, [3, 4]), we can suppose
that a history of infections and thus a possible vulner-
ability to them might be a common feature of persistent
adult ADHD. Future studies comparing remitters and
non-remitter adults should be conducted to confirm this
suggestion. Furthermore, the poor reliability of retro-
spective data collection could partially explain this con-
siderable discrepancy in rate history of infections
between adults and children and can not allow to dis-
cern streptococcus-related from other infections.
Even more emerged about basal ganglia autoimmunity
as over a fifth of the sample had positive ABGA titers,
consistently with a previous report regarding Italian chil-
dren with ADHD (25%, [28]). This rate was also in line
with that found in adults affected by obsessive-
compulsive disorder (19.8%, [35]), which represents one
of the most known neuropsychiatric manifestation of
post-streptococcal autoimmune basal ganglia disorders
[36]. ADHD seems to be even more prevalent than
obsessive-compulsive disorder in adult populations (2.8%
vs. 1.2%, [4, 37]) and, as mentioned above, the implica-
tion of structural and functional anomalies of basal gan-
glia in its pathophysiology has been well-recognized by
neuroimaging studies [5, 6, 8, 9]. However, the relation-
ship between ADHD and post-infective basal ganglia dis-
orders is little investigated, especially during adulthood,
when the neurodevelopment is expected to be complete,
Table 1 Sociodemographic and clinical features of the sample
(N = 22)
Features Value
Male, n (%) 12 (54.5%)
Age (years), Mdn ± IQR 30 ± 12
Education, n (%)
Middle school diploma 9 (40.9)
High school diploma 8 (36.4)
Bachelor’s degree 2 (9.1)
Master’s degree 3 (13.6)




Reference to ADHD outpatient center, n (%)
Autonomous 10 (45.5)
General Practitioner 4 (18.2)
Child neuropsychiatrist 2 (9.1)
ADHD subtype, n (%)
Predominantly inattentive 12 (54.5)
Predominantly hyperactive/impulsive 0 (0)
Combined 10 (45.5)
Positive family history of psychiatric disorders, n (%) 8 (36.4)
Positive family history of ADHD, n (%) 6 (27.3)
Psychiatric comorbidity, n (%) 8 (36.4)
Recurrent infections during childhood, n (%) 14 (63.6%)
Tonsillitis or adenoiditis 7 (31.8)
with Surgical removal 3 (13.6)
Rheumatic fever 3 (13.6)
Otitis 1 (4.5)
Mixed upperway infection 1 (4.5)
Glomerulonephritis 1 (4.5)
Pneumonia 1 (4.5)
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thus neither infections nor the autoimmunity process
can longer affect its course.
The main aim of the present study was to provide pre-
liminary findings on the usefulness of ASO, anti-DNase
B, and ABGA titers measurement in adult patients with
ADHD. In this respect, we used easily available, stand-
ard, ready-to-use ELISA kit tests for the quantitative de-
termination of blood titers that increased the
reproducibility of our research and findings.
Nevertheless, different limitations should be taken into
account. First of all, the sample size of the present study
was small, although it was not so far from those of some
clinical groups of previous case-control studies con-
ducted on children (n = 20, [28] and n = 22, [27]), which
however included a more or less appropriate control
group (i.e., healthy children or patients with neurological
disorders). In this regard, a noteworthy concern for fu-
ture studies could be establishing the right eligibility cri-
teria for a control group, given the impressive high
psychiatric comorbidity rate of ADHD in adulthood (i.e.,
non-ADHD patients matched for comorbidity, enroll-
ment season and age?). Another limitation can be recog-
nized in current GAS infection detection because the
inclusion of a rapid strep test or a pharyngeal swab cul-
ture would have been highly recommended to reach a
more informative assessment.
Further studies including appropriate controls should
be conducted on wider samples to confirm our prelimin-
ary findings, providing more solid evidence to support
the already suggested vulnerability of patients with
ADHD to some type of infections in childhood and per-
haps also in adulthood [26, 28]. Nevertheless, to evaluate
the trajectories of the relationship between childhood in-
fections and ADHD development, further studies might
consider ADHD remitters (i.e., adults without current
ADHD but who have had ADHD in childhood). Notably,
future studies may focus on a potential genetic predis-
position to infection or other environmental factors af-
fecting the neurodevelopment of the basal ganglia.
Conclusion
According to the present preliminary study, patients
with ADHD might be prone to infections during child-
hood, subclinical streptococcal infections in adulthood,
and they seem to have a high risk for basal ganglia auto-
immunity as adults. Both infections and the ensuing
acquired autoimmunity may influence the neurodevelop-
mental process, by contributing, at least in part, to the
ADHD pathogenesis. ASO, anti-DNase B and ABGA ti-
ters seem to be easy to determine by using specific
ELISA kits. It may be possible that a childhood predis-
position to infection, which persists into adulthood as
antistreptococcal titer positivity, might also contribute to
the pathogenesis of ADHD and even to its persistence.
Future controlled studies should confirm on wider sam-
ples our findings on streptococcal infections, auto-
immunity, and ADHD. As for some other
neuropsychiatric disorders, ADHD may be related to
streptococcal infections or basal ganglia autoimmunity
and this could have implications on pharmacological
treatment.
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